Cancer Medicine

Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

Annals of Hematology

Renin-angiotensin inhibitors reduce thrombotic complications in essential thrombocythemia and polycythemia vera patients with arterial hypertension

Annals of Hematology

Role of next generation immune checkpoint inhibitor (ICI) therapy in Philadelphia negative classic myeloproliferative neoplasm (MPN): Review of the literature

Cancer

New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-XL/BCL-2 inhibition with navitoclax

Annals of Hematology

Renin-angiotensin inhibitors reduce thrombotic complications in essential thrombocythemia and polycythemia vera patients with arterial hypertension

Cancer Medicine

Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

The Lancet Haematology

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

Cancers

Predictors of response to hydroxyurea and switch to ruxolitinib in HU-resistant polycythaemia vera patients: A real-world PV-NET study

Biomedicines

Identifying patients with polycythemia vera at risk of thrombosis after hydroxyurea initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) project

Journal of Hematology & Oncology

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety